NCT04544995 2026-01-21
Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)
GlaxoSmithKline
Phase 1 Terminated
GlaxoSmithKline
ImmunityBio, Inc.
Turning Point Therapeutics, Inc.
NanOlogy, LLC
NantBioScience, Inc.
Exscientia AI Limited
NanOlogy, LLC
Bayer
NanOlogy, LLC
Nova Laboratories Limited